Allergan, a division of the American biopharmaceutical company Abbvie, announced at the end of February that it has filed a new drug application with the U.S. Food and Drug Administration (FDA) for eye drops aimed at treating presbyopia. The ophthalmic solution has already been tested successfully with 750 patients, resulting in significant improvements in near vision even in low-light conditions. The FDA is expected to give its conclusions by the end of the year.